Vericel Corp

NASDAQ:VCELUnited States

Nov 7, 2024

Show headlines and story abstract

• Vericel's Q3 Net Loss Narrows, Revenue Increases, from 9:48AM ET on Thursday Nov 07, 2024 by MT Newswires

  9:48AM ET on Thursday Nov 07, 2024 by MT Newswires
  Companies Mentioned: VCEL
  09:48 AM EST, 11/07/2024 (MT Newswires) -- Vericel (VCEL) reported a Q3 net loss Thursday of $0.02 per diluted share, narrowing from a $0.08 net loss per share a year earlier. Analysts polled by Capital IQ expected a net loss of $0.05 per share. Rev...

• -- Earnings Flash (VCEL) VERICEL CORPORATION Posts Q3 Revenue $57.9M, from 7:55AM ET on Thursday Nov 07, 2024 by MT Newswires

  7:55AM ET on Thursday Nov 07, 2024 by MT Newswires
  Companies Mentioned: VCEL
  07:55 AM EST, 11/07/2024 (MT Newswires) -- ...

• Vericel Reports Third Quarter 2024 Financial Results, from 7:55AM ET on Thursday Nov 07, 2024 by Dow Jones

  7:55AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: VCEL
  
  or similar expressions.
  
  Among the factors that could cause actual results to differ materially from those set forth in the forward-looking statements include, but are not limited to, uncertainties associated with our expectations regarding future revenue, growth in revenue, market penetration for MACI, MACI Arthro, Epicel, and NexoBrid, growth in profit, gross margins and operating margins, the ability to continue to scale our manufacturing operations to meet the demand for our cell therapy products, including the timely completion of a new headquarters and manufacturing facility in Burlington, Massachusetts, the ability to achieve or sustain profitability, contributions to adjusted EBITDA, the expected target surgeon audience, potential fluctuations in sales and volumes and our results of operations over the course of the year, timing and conduct of clinical trial and product development activities, timing and likelihood of the FDA's potential approval of the use of MACI to treat cartilage defects in the ankle, the estimate of the commercial growth potential of our products and product candidates, competitive developments, changes in third-party coverage and reimbursement, surgeon adoption of MACI Arthro, physician and burn center adoption of NexoBrid, labor strikes, changes in surgeon and hospital treatment prioritizations caused by the temporary shortage of essential medical supplies, supply chain disruptions or other events or factors that might affect our ability to manufacture MACI or Epicel or affect MediWound's ability to manufacture and supply sufficient quantities of NexoBrid to meet customer demand, including but not limited to, damage or disruption caused by natural disasters and the ongoing military conflicts in the Middle East region involving Israel, negative impacts on the global economy and capital markets resulting from the conflict in Ukraine and the Middle East conflicts, adverse developments affecting financial institutions, companies in the financial services industry or the financial services industry generally, global geopolitical tensions or record inflation and the potential future impacts on our business or the economy generally stemming from a public health emergency.